{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T11:11:10Z","timestamp":1778757070668,"version":"3.51.4"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s11864-025-01310-y","type":"journal-article","created":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T02:08:45Z","timestamp":1743559725000},"page":"302-312","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Novel Estrogen Receptor \u2013 Targeted Therapies in Hormone-Receptor Positive Breast Cancer"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-8620-5740","authenticated-orcid":false,"given":"Nina E.","family":"Neill","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren A.","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Pennisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,31]]},"reference":[{"key":"1310_CR1","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov). SEER*Stat Database: Incidence \u2013 SEER Research Data, 8 Registries, Nov 2023 Sub (1945\u20132021)- Linked To Countyy Attributes \u2013 Time Dependent (1990\u20132022). Income\/ Rurality, 1696\u20132022 Counties, National Cancer, Institute, DCCPS, Surveillance Research Program, release April 2024, based on the November 2023 submission."},{"issue":"1","key":"1310_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41523-023-00523-4","volume":"9","author":"R Patel","year":"2023","unstructured":"Patel R, Klein P, Tiersten A, et al. an emerging generation of endocrine therapies in breast cancer: a clinical perspective. Npj Breast Cancer. 2023;9(1):1\u201312. https:\/\/doi.org\/10.1038\/s41523-023-00523-4.","journal-title":"Npj Breast Cancer"},{"key":"1310_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2017.12.012","volume":"186","author":"HK Patel","year":"2018","unstructured":"Patel HK, Bihani T. Selective Estrogen Receptor Modulators (SERMs) and Selective Estrogen Receptor Degraders (SERDs) in cancer treatment. Pharmacol Therapeutics. 2018;186:1\u201324. https:\/\/doi.org\/10.1016\/j.pharmthera.2017.12.012.","journal-title":"Pharmacol Therapeutics"},{"issue":"15","key":"1310_CR4","first-page":"3867","volume":"51","author":"AE Wakeling","year":"1991","unstructured":"Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res. 1991;51(15):3867\u201373.","journal-title":"Cancer Res"},{"issue":"5","key":"1310_CR5","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1002\/ijc.2910550529","volume":"55","author":"XF Hu","year":"1993","unstructured":"Hu XF, et al. Circumvention of tamoxifen resistance by the pure anti-estorgen ICI 182, 780. Int J Cancer. 1993;55(5):876\u2013876.","journal-title":"Int J Cancer"},{"issue":"30","key":"1310_CR6","doi-asserted-by":"publisher","first-page":"4594","DOI":"10.1200\/JCO.2010.28.8415","volume":"28","author":"A Di Leo","year":"2010","unstructured":"Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, et al. Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 Mg With Fulvestrant 500 Mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2010;28(30):4594\u2013600. https:\/\/doi.org\/10.1200\/JCO.2010.28.8415.","journal-title":"J Clin Oncol"},{"key":"1310_CR7","doi-asserted-by":"publisher","unstructured":"Di Leo, A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, et al. Final Overall Survival: Fulvestrant 500mg vs 250mg in the Randomized CONFIRM Trial, JNCI: J National Cancer Institute 2014 106(1). https:\/\/doi.org\/10.1093\/jnci\/djt337","DOI":"10.1093\/jnci\/djt337"},{"issue":"10063","key":"1310_CR8","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1016\/S0140-6736(16)32389-3","volume":"388","author":"JFR Robertson","year":"2016","unstructured":"Robertson JFR, Bondarenko IM, Trishkina E, Dvorkin M, Panasci L, et al. Fulvestrant 500 Mg versus Anastrozole 1 Mg for Hormone Receptor-Positive Advanced Breast Cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 2016;388(10063):2997\u20133005. https:\/\/doi.org\/10.1016\/S0140-6736(16)32389-3.","journal-title":"Lancet"},{"key":"1310_CR9","doi-asserted-by":"crossref","unstructured":"Robertson J. 384MO - Final overall survival analysis for fulvestrant vs anastrozole in endocrine therapy (ET)-na\u00efve, hormone receptor-positive (HR+) advanced breast cancer (FALCON). Presented at ESMO Congress 2023. Madrid, Spain.","DOI":"10.1016\/j.annonc.2023.09.561"},{"issue":"4","key":"1310_CR10","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"M Cristofanilli","year":"2016","unstructured":"Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, Colleoni M, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, her2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425\u201339. https:\/\/doi.org\/10.1016\/S1470-2045(15)00613-0.","journal-title":"Lancet Oncol"},{"issue":"24","key":"1310_CR11","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","volume":"36","author":"DJ Slamon","year":"2018","unstructured":"Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, et al. Phase III Randomized Study of Ribociclib and Fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36(24):2465\u201372. https:\/\/doi.org\/10.1200\/JCO.2018.78.9909.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1310_CR12","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13058-023-01701-9","volume":"25","author":"P Neven","year":"2023","unstructured":"Neven P, Fasching PA, Chia S, Jerusalem G, De Laurentiis M, Im SA, et al. Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+\/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant. Breast Cancer Res. 2023;25(1):103. https:\/\/doi.org\/10.1186\/s13058-023-01701-9.","journal-title":"Breast Cancer Res"},{"issue":"25","key":"1310_CR13","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","volume":"35","author":"GW Sledge","year":"2017","unstructured":"Sledge GW, Masakazu T, Neven P, Sohn J, Inoue L, et al. MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875\u201384. https:\/\/doi.org\/10.1200\/JCO.2017.73.7585.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1310_CR14","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1097\/CAD.0000000000000271","volume":"26","author":"F Garner","year":"2015","unstructured":"Garner F, Maysoun S, Paquin D, Lyttle CF, Hattersley G. RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models. Anticancer Drugs. 2015;26(9):948\u201356. https:\/\/doi.org\/10.1097\/CAD.0000000000000271.","journal-title":"Anticancer Drugs"},{"issue":"28","key":"1310_CR15","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1200\/JCO.22.00338","volume":"40","author":"FC Bidard","year":"2022","unstructured":"Bidard FC, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase iii emerald trial. J Clin Oncol: Off J Am Soc Clin Oncol. 2022;40(28):3246\u201356. https:\/\/doi.org\/10.1200\/JCO.22.00338.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"1310_CR16","doi-asserted-by":"crossref","unstructured":"Bardia A, Bidard FC, Neven P, et al: EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+\/HER2\u2013 metastatic breast cancer: Updated results by duration of prior CDK4\/6 inhibitor in metastatic setting. 2022 San Antonio Breast Cancer Symposium. Abstract GS3\u201301. Presented December 8, 2022.","DOI":"10.1158\/1538-7445.SABCS22-GS3-01"},{"key":"1310_CR17","doi-asserted-by":"crossref","unstructured":"Jhaveri KL, Im SA, Saura C, et al. Inavolisib or placebo in combination with palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer: Phase III INAVO120 primary analysis. Presented at the 2023 San Antonio Breast Cancer Symposium; December 5\u20139, 2023. San Antonio, Texas. Abstract GS03\u201313.","DOI":"10.1158\/1538-7445.SABCS23-GS03-13"},{"issue":"15_suppl","key":"1310_CR18","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1200\/JCO.2020.38.15_suppl.1023","volume":"38","author":"E Lim","year":"2020","unstructured":"Lim E, Jhaveri KL, Perez-Fidalgo J, Bellet M, Boni V, et al. A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer. J Clin Oncol. 2020;38(15_suppl):1023\u20131023. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.1023.","journal-title":"J Clin Oncol"},{"issue":"18","key":"1310_CR19","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1200\/JCO.23.01500","volume":"42","author":"M Mart\u00edn","year":"2024","unstructured":"Mart\u00edn M, Lim E, Chavez-MacGregor M, Bardia A, Wu J, Zhang Q, et al. Giredestrant for estrogen receptor-positive, HER2-negative, previously treated advanced breast cancer: results from the randomized, phase II acelERA breast cancer study. J Clin Oncol. 2024;42(18):2149\u201360. https:\/\/doi.org\/10.1200\/JCO.23.01500.","journal-title":"J Clin Oncol"},{"key":"1310_CR20","doi-asserted-by":"crossref","unstructured":"Oliveira M, Pominchuk D, Nowecki Z, et al. Camizestrant, a next-generation oral SERD, vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose phase 2 SERENA-2 trial. 2022 San Antonio Breast Cancer Symposium. Abstract GS3\u201302. Presented December 8, 2022.","DOI":"10.1158\/1538-7445.SABCS22-GS3-02"},{"issue":"15","key":"1310_CR21","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1200\/JCO.2021.39.15_suppl.1063","volume":"39","author":"M Maglakelidze","year":"2021","unstructured":"Maglakelidze M, Bulat I, Ryspayeva D, Krastev BM, Gogiladze M, Crijanovschi A, et al. Rintodestrant (G1T48), an oral selective estrogen receptor degrader, in combination with palbociclib for ER+\/HER2\u2013 advanced breast cancer: Phase 1 results. J Clin Oncol. 2021;39(15):1063\u20131063. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.1063.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1310_CR22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41571-023-00840-4","volume":"21","author":"L Morrison","year":"2024","unstructured":"Morrison L, Loibl S, Turner NC. The CDK4\/6 inhibitor revolution \u2014 a game-changing era for breast cancer treatment. Nat Rev Clin Oncol. 2024;21(2):89\u2013105. https:\/\/doi.org\/10.1038\/s41571-023-00840-4.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"1310_CR23","first-page":"216","volume":"32","author":"M Shah","year":"2021","unstructured":"Shah M, Nunes MM, Stearns V. CDK4\/6 inhibitors: game changers in the management of hormone receptor\u2013positive advanced breast cancer? Oncology. 2021;32(5):216\u201322.","journal-title":"Oncology"},{"issue":"7","key":"1310_CR24","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nrclinonc.2016.26","volume":"13","author":"B O\u2019Leary","year":"2016","unstructured":"O\u2019Leary B, Finn RS, Turner NC. Treating cancer with selective CDK4\/6 inhibitors. Nat Rev Clin Oncol. 2016;13(7):417\u201330. https:\/\/doi.org\/10.1038\/nrclinonc.2016.26.","journal-title":"Nat Rev Clin Oncol"},{"key":"1310_CR25","doi-asserted-by":"publisher","first-page":"693104","DOI":"10.3389\/fonc.2021.693104","volume":"11","author":"MA George","year":"2021","unstructured":"George MA, Qureshi S, Omene C, Toppmeyer DL, Ganesan S. Clinical and pharmacologic differences of CDK4\/6 inhibitors in breast cancer. Front Oncol. 2021;11:693104. https:\/\/doi.org\/10.3389\/fonc.2021.693104.","journal-title":"Front Oncol"},{"issue":"20","key":"1310_CR26","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, Harbeck N, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925\u201336. https:\/\/doi.org\/10.1056\/NEJMoa1607303.","journal-title":"N Engl J Med"},{"key":"1310_CR27","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s10549-018-05125-4","volume":"174","author":"HS Rugo","year":"2019","unstructured":"Rugo HS, Finn RS, Di\u00e9ras V, et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res Treat. 2019;174:719\u201329. https:\/\/doi.org\/10.1007\/s10549-018-05125-4.","journal-title":"Breast Cancer Res Treat"},{"key":"1310_CR28","doi-asserted-by":"crossref","unstructured":"Finn RS, et al. Overall survival (OS) with first-line palbociclib plus letrozole (PAL plus LET) versus placebo plus letrozole (PBO plus LET) in women with estrogen receptor positive\/human epidermal growth factor receptor 2-negative advanced breast cancer (ER+\/HER2\u2212 ABC): analyses from PALOMA-2 [abstract]. J. Clin. Oncol. 2022; 40(Suppl. 17):LBA1003.","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA1003"},{"issue":"7","key":"1310_CR29","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","volume":"29","author":"GN Hortobagyi","year":"2018","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018;29(7):1541\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdy155.","journal-title":"Ann Oncol"},{"issue":"10","key":"1310_CR30","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1056\/NEJMoa2114663","volume":"386","author":"GN Hortobagyi","year":"2022","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Hart L, Campone M, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med. 2022;386(10):942\u201350. https:\/\/doi.org\/10.1056\/NEJMoa2114663.","journal-title":"N Engl J Med"},{"issue":"1","key":"1310_CR31","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41523-018-0097-z","volume":"5","author":"S Johnston","year":"2019","unstructured":"Johnston S, Martin M, Di Le A, Im SA, Awada A, Forrester T, Frenzel M, et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. Npj Breast Cancer. 2019;5(1):5. https:\/\/doi.org\/10.1038\/s41523-018-0097-z.","journal-title":"Npj Breast Cancer"},{"key":"1310_CR32","unstructured":"Johnston S, et al. MONARCH-3: Final overall survival results with abemaciclib-based therapy for advanced breast cancer. San Antonio Breast Cancer Symposium, 2023."},{"issue":"7","key":"1310_CR33","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","volume":"19","author":"D Tripathy","year":"2018","unstructured":"Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, Hurvitz SA, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19(7):904\u201315. https:\/\/doi.org\/10.1016\/S1470-2045(18)30292-4.","journal-title":"Lancet Oncol"},{"issue":"5","key":"1310_CR34","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1158\/1078-0432.CCR-21-3032","volume":"28","author":"YS Lu","year":"2022","unstructured":"Lu YS, Im SA, Colleoni M, Franke F, Bardia A, Cardoso F, Harbeck N, Hurvitz S, et al. Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+\/HER2- advanced breast cancer in MONALEESA-7: a phase iii randomized clinical trial. Clin Cancer Res: Off J Am Assoc Cancer Res. 2022;28(5):851\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3032.","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"issue":"16","key":"1310_CR35","doi-asserted-by":"publisher","first-page":"3433","DOI":"10.1158\/1078-0432.CCR-22-0305","volume":"28","author":"M Cristofanilli","year":"2022","unstructured":"Cristofanilli M, Rugo HS, Im SA, Slamon DJ, Harbeck N, Bondarenko I, Masuda N, et al. Overall Survival with Palbociclib and Fulvestrant in Women with HR+\/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study. Clin Cancer Res: Off J Am Assoc Cancer Res. 2022;28(16):3433\u201342. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-0305.","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"key":"1310_CR36","doi-asserted-by":"publisher","unstructured":"Sonke GS, Van Ommen-Nijhof A, Wortelboer N, van der Noort V, Swinkels AC, Blommestein HM, Jager A. Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017\u201303) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4\/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC). J Clin Oncol. 2023;41:17_suppl, LBA1000-LBA1000. https:\/\/doi.org\/10.1200\/JCO.2023.41.17_suppl.LBA1000","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA1000"},{"issue":"6","key":"1310_CR37","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1911149","volume":"382","author":"DJ Slamon","year":"2020","unstructured":"Slamon DJ, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med. 2020;382(6):514\u201324. https:\/\/doi.org\/10.1056\/NEJMoa1911149.","journal-title":"N Engl J Med"},{"issue":"25","key":"1310_CR38","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","volume":"35","author":"GW Sledge","year":"2017","unstructured":"Sledge GW, Toi M, Neven P, Sohn JIK, Pivot X, Burdaeva O, et al. MONARCH 2: Abemaciclib in combination with fulvestrant in women With HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol: Off J Am Soc Clin Oncol. 2017;35(25):2875\u201384. https:\/\/doi.org\/10.1200\/JCO.2017.73.7585.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"5","key":"1310_CR39","first-page":"PD13","volume":"83","author":"A Llombart-Cussac","year":"2023","unstructured":"Llombart-Cussac A, et al. Final overall survival analysis of monarch 2: a phase 3 trial of abemaciclib plus fulvestrant in patients with hormone receptor-positive, HER2-negative advanced breast cancer [abstract]. Cancer Res. 2023;83(5):PD13-11.","journal-title":"Cancer Res"},{"key":"1310_CR40","doi-asserted-by":"crossref","unstructured":"Kalinsky K, Accordino MK, Chiuzan C, Mundi PS, Trivedi MS, Novik Y, Tiersten A, Raptis G., Baer LN, Young Oh S, et al. A Randomized, Phase II Trial of Fulvestrant Or Exemestane with Or without Ribociclib After Progression on Anti-Estrogen Therapy Plus Cyclin-Dependent Kinase 4\/6 Inhibition (CDK 4\/6i) in Patients (Pts) with Unresectable Or Hormone Receptor\u2013positive (HR+), HER2\u2212Negative Metastatic Breast Cancer (MBC): MAINTAIN Trial. JCO. 2022;40:LBA1004.","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA1004"},{"issue":"17","key":"1310_CR41","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1200\/JCO.23.01940","volume":"42","author":"EL Mayer","year":"2024","unstructured":"Mayer EL, Ren Y, Wagle N, Mahtani R, Ma C, DeMichele A, Cristofanilli M, Meisel J, Miller KD, Abdou Y, Riley EC, Qamar R, Sharma P, Reid S, Sinclair N, Faggen M, Block CC, Ko N, Partridge AH, Chen WY, DeMeo M, Attaya V, Okpoebo A, Alberti J, Liu Y, Gauthier E, Burstein HJ, Regan MM, Tolaney SM. PACE: A randomized phase II study of fulvestrant, palbociclib, and avelumab after progression on cyclin-dependent kinase 4\/6 inhibitor and aromatase inhibitor for hormone receptor-positive\/human epidermal growth factor receptor-negative metastatic breast cancer. J Clin Oncol. 2024;42(17):2050\u201360. https:\/\/doi.org\/10.1200\/JCO.23.01940.","journal-title":"J Clin Oncol"},{"issue":"34","key":"1310_CR42","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1200\/JCO.20.02514","volume":"38","author":"SRD Johnston","year":"2020","unstructured":"Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, Zhang QY, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2\u2212, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38(34):3987\u201398. https:\/\/doi.org\/10.1200\/JCO.20.02514.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1310_CR43","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","volume":"390","author":"D Slamon","year":"2024","unstructured":"Slamon D, Lipatov O, Nowecki Z, McAndrew N, Kukielka-Budny B, Stroyakovskiy D, Yardley DA, et al. Ribociclib plus endocrine therapy in early breast cancer. N Engl J Med. 2024;390(12):1080\u201391. https:\/\/doi.org\/10.1056\/NEJMoa2305488.","journal-title":"N Engl J Med"},{"issue":"7","key":"1310_CR44","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nrc839","volume":"2","author":"I Vivanco","year":"2002","unstructured":"Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2(7):489\u2013501. https:\/\/doi.org\/10.1038\/nrc839.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"1310_CR45","doi-asserted-by":"publisher","first-page":"R21","DOI":"10.1186\/bcr2833","volume":"13","author":"CG Sanchez","year":"2011","unstructured":"Sanchez CG, Ma CX, Crowder RJ, Guintoli T, Phommaly C, Gao F, et al. modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Res: BCR. 2011;13(2):R21. https:\/\/doi.org\/10.1186\/bcr2833.","journal-title":"Breast Cancer Res: BCR"},{"issue":"7","key":"1310_CR46","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1172\/JCI41680","volume":"120","author":"TW Miller","year":"2010","unstructured":"Miller TW, Hennessy BT, Gonz\u00e1lez-Angulo AM, Fox EM, Mills GB, et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Investig. 2010;120(7):2406\u201313. https:\/\/doi.org\/10.1172\/JCI41680.","journal-title":"J Clin Investig"},{"issue":"12","key":"1310_CR47","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1001\/jamaoncol.2016.0891","volume":"2","author":"SZ Millis","year":"2016","unstructured":"Millis SZ, Ikeda S, Reddy S, Gatalica Z, Kurzrock R. Landscape of Phosphatidylinositol-3-Kinase pathway alterations across 19 784 diverse solid tumors. JAMA Oncol. 2016;2(12):1565\u201373. https:\/\/doi.org\/10.1001\/jamaoncol.2016.0891.","journal-title":"JAMA Oncol"},{"issue":"3","key":"1310_CR48","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ccell.2018.08.008","volume":"34","author":"P Razavi","year":"2018","unstructured":"Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, Cai Y, et al. The genomic landscape of endocrine-resistant advanced breast cancers. Cancer Cell. 2018;34(3):427-438.e6. https:\/\/doi.org\/10.1016\/j.ccell.2018.08.008.","journal-title":"Cancer Cell"},{"issue":"4","key":"1310_CR49","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(21)00034-6","volume":"22","author":"HS Rugo","year":"2021","unstructured":"Rugo HS, Lerebours F, Ciruelos E, Drullinsky P, Ruiz-Borrego M, Neven P, et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4\/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol. 2021;22(4):489\u201398. https:\/\/doi.org\/10.1016\/S1470-2045(21)00034-6.","journal-title":"Lancet Oncol"},{"issue":"10","key":"1310_CR50","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1007\/s12325-013-0060-1","volume":"30","author":"DA Yardley","year":"2013","unstructured":"Yardley DA, Noguchi S, Pritchard KI, Burris HA, Baselga J, et al. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther. 2013;30(10):870\u201384. https:\/\/doi.org\/10.1007\/s12325-013-0060-1.","journal-title":"Adv Ther"},{"issue":"5","key":"1310_CR51","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/S1470-2045(1730109-2","volume":"18","author":"HS Rugo","year":"2017","unstructured":"Rugo HS, Seneviratne L, Beck JT, Glaspy JA, Peguero JA, et al. Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. Lancet Oncol. 2017;18(5):654\u201362. https:\/\/doi.org\/10.1016\/S1470-2045(1730109-2.","journal-title":"Lancet Oncol"},{"issue":"22","key":"1310_CR52","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1200\/JCO.2011.39.0708","volume":"30","author":"T Bachelot","year":"2012","unstructured":"Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol: Off J Am Soc Clin Oncol. 2012;30(22):2718\u201324. https:\/\/doi.org\/10.1200\/JCO.2011.39.0708.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"16","key":"1310_CR53","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1200\/JCO.2017.76.9331","volume":"36","author":"N Kornblum","year":"2018","unstructured":"Kornblum N, Zhao F, Manola J, Klein P, Ramaswamy B, Brufsky A, et al. Randomized phase II trial of fulvestrant plus everolimus or placebo in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer resistant to aromatase inhibitor therapy: Results of PrE0102. J Clin Oncol: Off J Am Soc Clin Oncol. 2018;36(16):1556\u201363. https:\/\/doi.org\/10.1200\/JCO.2017.76.9331.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"1310_CR54","doi-asserted-by":"publisher","first-page":"e5092","DOI":"10.7717\/peerj.5092","volume":"6","author":"H Qin","year":"2018","unstructured":"Qin H, Liu L, Sun S, Zhang D, Sheng J, Li B, Yang W. The impact of PI3K inhibitors on breast cancer cell and its tumor microenvironment. PeerJ. 2018;6:e5092. https:\/\/doi.org\/10.7717\/peerj.5092.","journal-title":"PeerJ"},{"issue":"1","key":"1310_CR55","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nrc3860","volume":"15","author":"LM Thorpe","year":"2015","unstructured":"Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer. 2015;15(1):7\u201324. https:\/\/doi.org\/10.1038\/nrc3860.","journal-title":"Nat Rev Cancer"},{"issue":"21","key":"1310_CR56","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1056\/NEJMra1704560","volume":"379","author":"MD Goncalves","year":"2018","unstructured":"Goncalves MD, Hopkins BD, Cantley LC. Phosphatidylinositol 3-Kinase, growth disorders, and cancer. N Engl J Med. 2018;379(21):2052\u201362. https:\/\/doi.org\/10.1056\/NEJMra1704560.","journal-title":"N Engl J Med"},{"issue":"4","key":"1310_CR57","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1177\/1758834014530023","volume":"6","author":"E Paplomata","year":"2014","unstructured":"Paplomata E, O\u2019Regan R. The PI3K\/AKT\/mTOR pathway in breast cancer: targets, trials and biomarkers. Therapeutic Adv Med Oncol. 2014;6(4):154\u201366. https:\/\/doi.org\/10.1177\/1758834014530023.","journal-title":"Therapeutic Adv Med Oncol"},{"issue":"6","key":"1310_CR58","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/bcr3039","volume":"13","author":"TW Miller","year":"2011","unstructured":"Miller TW, Rexer BN, Garrett JT, Arteaga CL. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res: BCR. 2011;13(6):224. https:\/\/doi.org\/10.1186\/bcr3039.","journal-title":"Breast Cancer Res: BCR"},{"issue":"4","key":"1310_CR59","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","volume":"170","author":"DA Fruman","year":"2017","unstructured":"Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. The PI3K Pathway in Human Disease. Cell. 2017;170(4):605\u201335. https:\/\/doi.org\/10.1016\/j.cell.2017.07.029.","journal-title":"Cell"},{"key":"1310_CR60","doi-asserted-by":"publisher","unstructured":"Juric D, Rodon J, Tabernero J, Janku F, Burris HA, Schellens JHM, et al. 3-Kinase \u03b1-selective inhibition with Alpelisib (BYL719) in PIK3CA-Altered solid tumors: results from the first-in-human study. J Clin Oncol: Off J Amer Soc Clin Oncol. 2018; 36(13):1291\u20131299. https:\/\/doi.org\/10.1200\/JCO.2017.72.7107","DOI":"10.1200\/JCO.2017.72.7107"},{"issue":"3","key":"1310_CR61","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S1470-2045(19)30817-4","volume":"21","author":"RH Jones","year":"2020","unstructured":"Jones RH, Casbard A, Carucci M, Cox C, Butler R, Alchami F, Madden TA, et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2020;21(3):345\u201357. https:\/\/doi.org\/10.1016\/S1470-2045(19)30817-4.","journal-title":"Lancet Oncol"},{"issue":"7","key":"1310_CR62","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S1470-2045(22)00284-4","volume":"23","author":"SJ Howell","year":"2022","unstructured":"Howell SJ, Casbard A, Carucci M, Ingarfield K, Butler R, Morgan S, et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. Lancet Oncol. 2022;23(7):851\u201364.","journal-title":"Lancet Oncol."}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01310-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-025-01310-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01310-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T05:45:01Z","timestamp":1744350301000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-025-01310-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,31]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1310"],"URL":"https:\/\/doi.org\/10.1007\/s11864-025-01310-y","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,31]]},"assertion":[{"value":"17 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr Angela Pennisi and Dr Lauren Mauro conduct clinical trials accruing patients with Astrazeneca, Eli Lilly, Stemline Therapeutics, Radius Pharmaceutical, and Genentech. Dr Lauren Mauro reports personal fees from Eli Lilly and Astrazenca.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors did not receive financial support from any organization for the submitted work. Dr Pennisi is involved in clinical trials accruing patients for Eli Lilly, Astazeneca, Stemline Therapeutics, Radius Therapeutics, and Genentech. Dr Mauro has received speaking fees from Eli Lilly, consulting fees from Astrazeneca and is currently involved in clinical trials recruiting patients for Stemline Therapeutics, Radius Therapeutics, and Genentech. Dr Neill has no interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosers"}}]}}